Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by
stimulating a person's white blood cells to kill their tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of interleukin-12 in treating patients
with AIDS -related Kaposi's sarcoma.